We previously took advantage of the yeast model system to study the effect of two CPT-resistance-conferring Top1 mutants identified in human cancer cells [11], hTop1W763Stop mutation—resulting in the truncation of three C-terminal residues—which was identified in a non-small cell lung cancer patients treated with the CPT-derivative irinotecan [18]. The gene discussed is TOP1; the disease is cancer.